Karyopharm Therapeutics/KPTI

$1.13

0%
-
1D1W1MYTD1YMAX

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Ticker

KPTI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Paulson

Employees

325

Headquarters

Newton center, United States

KPTI Metrics

BasicAdvanced
$136.26M
Market cap
-
P/E ratio
-$1.25
EPS
0.14
Beta
-
Dividend rate
$136.26M
0.14171
$4.11
$0.62
1.76M
3.367
3.323
-10.06%
-47.81%
-61.78%
0.933
-7.03%
38.31%
10.55%

What the Analysts think about KPTI

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
392.92% upside
High $8.00
Low $3.00
$1.13
Current price
$5.57
Average price target

KPTI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-124.03% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$33.7M
-6.39%
Net income
$-41.8M
21.16%
Profit margin
-124.03%
29.43%

KPTI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.24%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.30
-$0.29
-$0.30
-$0.36
-
Expected
-$0.37
-$0.34
-$0.28
-$0.31
-$0.33
Surprise
-18.53%
-15.26%
7.14%
16.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Karyopharm Therapeutics stock?

Karyopharm Therapeutics (KPTI) has a market cap of $136.26M as of April 23, 2024.

What is the P/E ratio for Karyopharm Therapeutics stock?

The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of April 23, 2024.

Does Karyopharm Therapeutics stock pay dividends?

No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Karyopharm Therapeutics dividend payment date?

Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.

What is the beta indicator for Karyopharm Therapeutics?

Karyopharm Therapeutics (KPTI) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Karyopharm Therapeutics stock price target?

The target price for Karyopharm Therapeutics (KPTI) stock is $5.57, which is 392.92% above the current price of $1.13. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Karyopharm Therapeutics stock

Buy or sell Karyopharm Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing